Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Weighing the Risks: Vivus View of Regulatory Risks in Qnexa Reprise

This article was originally published in RPM Report

Executive Summary

A good-news press release from Vivus on the resubmission and acceptance of its application to FDA for the weight-loss drug Qnexa contains an unusually long and descriptive list of the risks involved in the application. This more than boiler-plate “forward-looking” statement adds new interest to the sport of footnote-analysis.


Related Content

Setting the Stage: Qnexa and the Power of REMS
The Real Obesity Drugs Hurdle: Paying for Them
FDA Rethinking Weight Loss Standards: A Test Case for Patient-Focused Drug Development
A Tale of Two Drugs: Meridia and Avandia, and the Issues that Separated Them
The Year of the Unpartnered Blockbuster? High Profile Applications Raise Big Questions


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts